[Chronic ischemia of the small intestine in carcinoid tumor].

Z. Wieczorek,C. Sadliński,S. Kuśmierski,M. Luciak,J. Starzewski,M. Kawecki

1980-07-21

Abstract:

What problem does this paper attempt to address?

Irreversible Electroporation for the Treatment of Brain Tumors: Pre-clinical Results in a Canine Model of Spontaneous Glioma

John H. Rossmeisl,Paulo A. Garcia,John L. Robertson,Rafael V. Davalos

DOI: https://doi.org/10.1007/978-3-319-11128-5_201

2015-01-01

Abstract:Irreversible electroporation (IRE) is a nonthermal ablation technique that has been used for the treatment of numerous solid tumors. However, it has not been rigorously evaluated for use in brain tumors. Here we report the results of a pre-clinical study evaluating the safety of the NanoKnife IRE System for the treatment of spontaneous intracranial gliomas in a canine model. Client-owned dogs with biopsy-confirmed cerebral gliomas were eligible. Patient-specific treatment plans were generated using MRI-based tissue segmentation, volumetric meshing, and finite element modeling. IRE treatment was delivered using pulse parameters and electrode configurations derived from therapeutic plans using the NanoKnife System. The primary end point was an evaluation of safety over the 14 days immediately following treatment. Follow-up was continued for 1 year with serial neurological, laboratory, and brain MRI examinations.Seven dogs with gliomas were treated. The mean age of patients was 9.3 +/- 1.6 years, and the mean pre-treatment tumor volume was 1.9 +/- 1.4 cm3. The median preoperative Karnofsky Performance Score (KPS) was 70 (range, 30-75). Severe post-treatment toxicity was observed in 2/7 dogs, one of which developed fatal aspiration pneumonia and the other treatment associated cerebral edema, which resulted in transient neurological deterioration. Post-treatment diagnostic imaging, tumor biopsies, and neurological examinations indicated that tumor ablation was achieved without significant direct neurotoxicity in 6/7 dogs. The 14 day post-IRE KPS of the 6/7 dogs surviving to discharge was improved over pretreatment values in all cases. Objective tumor responses were seen in 4/5 (80%) of dogs with quantifiable MRI target lesions. The median survival was 119 days (range, 1 to > 840 days).With the incorporation of additional therapeutic planning techniques, the NanoKnife System is a novel technology capable of rapid and controlled IRE ablation of cerebral gliomas.
High-Frequency Irreversible Electroporation for Intracranial Meningioma: A Feasibility Study in a Spontaneous Canine Tumor Model

Eduardo L. Latouche,Christopher B. Arena,Jill W. Ivey,Paulo A. Garcia,Theresa E. Pancotto,Noah Pavlisko,Scott S. Verbridge,Rafael V. Davalos,John H. Rossmeisl

DOI: https://doi.org/10.1177/1533033818785285

2018-01-01

Abstract:High-frequency irreversible electroporation is a nonthermal method of tissue ablation that uses bursts of 0.5- to 2.0-microsecond bipolar electric pulses to permeabilize cell membranes and induce cell death. High-frequency irreversible electroporation has potential advantages for use in neurosurgery, including the ability to deliver pulses without inducing muscle contraction, inherent selectivity against malignant cells, and the capability of simultaneously opening the blood-brain barrier surrounding regions of ablation. Our objective was to determine whether high-frequency irreversible electroporation pulses capable of tumor ablation could be delivered to dogs with intracranial meningiomas. Three dogs with intracranial meningiomas were treated. Patient-specific treatment plans were generated using magnetic resonance imaging-based tissue segmentation, volumetric meshing, and finite element modeling. Following tumor biopsy, high-frequency irreversible electroporation pulses were stereotactically delivered in situ followed by tumor resection and morphologic and volumetric assessments of ablations. Clinical evaluations of treatment included pre- and posttreatment clinical, laboratory, and magnetic resonance imaging examinations and adverse event monitoring for 2 weeks posttreatment. High-frequency irreversible electroporation pulses were administered successfully in all patients. No adverse events directly attributable to high-frequency irreversible electroporation were observed. Individual ablations resulted in volumes of tumor necrosis ranging from 0.25 to 1.29 cm3. In one dog, nonuniform ablations were observed, with viable tumor cells remaining around foci of intratumoral mineralization. In conclusion, high-frequency irreversible electroporation pulses can be delivered to brain tumors, including areas adjacent to critical vasculature, and are capable of producing clinically relevant volumes of tumor ablation. Mineralization may complicate achievement of complete tumor ablation.

oncology
Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma

Paulo A. Garcia,Bor Kos,John H. Rossmeisl,Denis Pavliha,Damijan Miklavčič,Rafael V. Davalos

DOI: https://doi.org/10.1002/mp.12401

IF: 4.506

2017-07-25

Medical Physics

Abstract:PURPOSE: Irreversible electroporation (IRE) has been developed as a promising minimally invasive treatment to ablate spontaneous brain tumors with pulsed electric fields in canine patients. The purpose of the study is to determine the Peleg-Fermi parameters needed to incorporate pulse number and pulse duration into the therapeutic planning of IRE.METHODS: Seven canine patients were treated with IRE for spontaneous malignant glioma with MRI-based treatment planning. The treatment planning method consists of building patient-specific finite element models and using them to compute electric fields used in the IRE treatment. We evaluate the predictive power of tumor coverage with electric field alone vs. cell kill probability using radiographically confirmed clinical outcomes.RESULTS: Results of post-treatment diagnostic imaging, tumor biopsies, and neurological examinations indicated successful tumor ablation without significant direct neurotoxicity in six of the seven dogs. Objective tumor responses were seen in four (80%) of five dogs with quantifiable target lesions according to RANO criteria. Two dogs experienced survivals in excess of 1 yr, including one dog that resulted in complete response to IRE treatment for 5+ years to date. Tumor fraction exposed to electric field over 600 V/cm was between 0.08 and 0.73, while tumor fraction exposed to electric field over 300 V/cm was between 0.17 and 0.95. Probability of cell kill of ≥ 90% was found in tumor volume fractions between 0.21 and 0.99.CONCLUSIONS: We conclude that IRE is a safe and effective minimally invasive treatment for malignant glioma and can be predicted with the Peleg-Fermi cell kill probability function. A tumor coverage of ≥ 0.9 at a cell kill probability ≥ 90% can be used to guide IRE treatments of spontaneous malignant glioma based on the radiographically confirmed clinical outcomes achieved.

radiology, nuclear medicine & medical imaging
Mechanical Nanosurgery of Chemoresistant Glioblastoma Using Magnetically Controlled Carbon Nanotubes

Xian Wang,Zheyuan Gong,Tiancong Wang,Junhui Law,Xin Chen,Siyi Wanggou,Jintian Wang,Binbin Ying,Michelle Francisco,Weifan Dong,Yi Xiong,Jerry J. Fan,Graham MacLeod,Stephane Angers,Xuejun Li,Peter B. Dirks,Xinyu Liu,Xi Huang,Yu Sun

DOI: https://doi.org/10.1126/sciadv.ade5321

IF: 13.6

2023-01-01

Science Advances

Abstract:Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Despite multimodal treatment including surgery, radiotherapy, and chemotherapy, median patient survival has remained at ~15 months for decades. This situation demands an outside-the-box treatment approach. Using magnetic carbon nanotubes (mCNTs) and precision magnetic field control, we report a mechanical approach to treat chemoresistant GBM. We show that GBM cells internalize mCNTs, the mobilization of which by rotating magnetic field results in cell death. Spatiotemporally controlled mobilization of intratumorally delivered mCNTs suppresses GBM growth in vivo. Functionalization of mCNTs with anti-CD44 antibody, which recognizes GBM cell surface-enriched antigen CD44, increases mCNT recognition of cancer cells, prolongs mCNT enrichment within the tumor, and enhances therapeutic efficacy. Using mouse models of GBM with upfront or therapy-induced resistance to temozolomide, we show that mCNT treatment is effective in treating chemoresistant GBM. Together, we establish mCNT-based mechanical nanosurgery as a treatment option for GBM.
Intracranial nonthermal irreversible electroporation: in vivo analysis

Paulo A Garcia,John H Rossmeisl Jr,Robert E Neal 2nd,Thomas L Ellis,John D Olson,Natalia Henao-Guerrero,John Robertson,Rafael V Davalos

DOI: https://doi.org/10.1007/s00232-010-9284-z

Abstract:Nonthermal irreversible electroporation (NTIRE) is a new minimally invasive technique to treat cancer. It is unique because of its nonthermal mechanism of tumor ablation. Intracranial NTIRE procedures involve placing electrodes into the targeted area of the brain and delivering a series of short but intense electric pulses. The electric pulses induce irreversible structural changes in cell membranes, leading to cell death. We correlated NTIRE lesion volumes in normal brain tissue with electric field distributions from comprehensive numerical models. The electrical conductivity of brain tissue was extrapolated from the measured in vivo data and the numerical models. Using this, we present results on the electric field threshold necessary to induce NTIRE lesions (495-510 V/cm) in canine brain tissue using 90 50-mus pulses at 4 Hz. Furthermore, this preliminary study provides some of the necessary numerical tools for using NTIRE as a brain cancer treatment. We also computed the electrical conductivity of brain tissue from the in vivo data (0.12-0.30 S/m) and provide guidelines for treatment planning and execution. Knowledge of the dynamic electrical conductivity of the tissue and electric field that correlates to lesion volume is crucial to ensure predictable complete NTIRE treatment while minimizing damage to surrounding healthy tissue.
EXTH-52. GLIOBLASTOMA-TARGETING AUTOLOGOUS INDUCED NEURAL STEM CELL THERAPY: EVALUATING SAFETY, TOXICITY, PERSISTENCE, AND TRANSPLANT METHODS IN A POST-SURGICAL CANINE MODEL

Hunter Bomba,Kevin Sheets,Alain Valdivia,Simon Khagi,Laura Ruterbories,Christopher Mariani,Luke Borst,Debra Tokarz,Shawn Hingtgen

DOI: https://doi.org/10.1093/neuonc/noaa215.406

2020-11-01

Abstract:Abstract BACKGROUND Glioblastoma patient survival statistics have remained unchanged for more than three decades. Despite tumor resection and chemoradiotherapy, recurrence is inevitable. Moreover, the invasive behavior of glioblastoma confounds treatment. To improve patient survival statistics, a targeted therapy that can home to distant tumor foci is desperately needed. Induced neural stem cells (iNSCs) armed with cytotoxic payloads have proven efficacious against human xenograft models of glioblastoma. To further propel iNSCs to human clinical trials, we investigated the safety, toxicity, and persistence of iNSCs in a canine model. METHODS Autologous iNSCs generated from the skin of four non-tumor-bearing, purpose-bred, male beagles were engineered to express TRAIL and thymidine kinase (TK). iNSCs were loaded with ferumoxytol to facilitate MRI-tracking. Canines were divided into two cohorts to denote iNSC administration route: scaffold encapsulation or intracerebroventricular (ICV). Two dose levels were investigated: 1′106 iNSCs/kg or 3′106 iNSCs/kg. The scaffold cohort received a single dose of iNSCs while the ICV cohort received three doses of iNSCs via a Rickham reservoir. To activate TK, canines were administered valganciclovir. Canine health was assessed via neurological exams, MRI, and serial blood, urine, and CSF analyses. RESULTS No acute injection reactions were observed. Three of four canines exhibited surgery-induced blindness. Urine and CSF analyses were unremarkable. Unexpectedly, blood analyses showed transient neutropenia. Hypodense signal was observed on all MRI sequences through endpoint. Post-mortem histopathology of the spleen, liver, and lung were unremarkable. As expected, brain tissues exhibited gliosis, fibrous thickening, and inflammation. Spinal cords exhibited acute hemorrhaging, attributed to perimortem CSF draws. Surprisingly, significant testicular degeneration was observed; this was confirmed to be caused by valganciclovir. In conclusion, iNSCs exhibit limited toxicity and warrant further exploration. FUTURE DIRECTIONS Prospective studies will investigate the efficacy of autologous iNSCs in a spontaneous canine glioma model in preparation for human clinical trials.

oncology,clinical neurology
Neuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs

Laura Eling,Samy Kefs,Sarvenaz Keshmiri,Jacques Balosso,Susan Calvet,Gabriel Chamel,Renaud Drevon-Gaud,Isabelle Flandin,Maxime Gaudin,Lucile Giraud,Jean Albert Laissue,Paolo Pellicioli,Camille Verry,Jean-François Adam,Raphaël Serduc

DOI: https://doi.org/10.3390/cancers16152701

2024-07-30

Cancers

Abstract:Synchrotron Microbeam Radiation Therapy (MRT) has repeatedly proven its superiority compared with conventional radiotherapy for glioma control in preclinical research. The clinical transfer phase of MRT has recently gained momentum; seven dogs with suspected glioma were treated under clinical conditions to determine the feasibility and safety of MRT. We administered a single fraction of 3D-conformal, image-guided MRT. Ultra-high-dose rate synchrotron X-ray microbeams (50 μm-wide, 400 μm-spaced) were delivered through five conformal irradiation ports. The PTV received ~25 Gy peak dose (within microbeams) per port, corresponding to a minimal cumulated valley dose (diffusing between microbeams) of 2.8 Gy. The dogs underwent clinical and MRI follow-up, and owner evaluations. One dog was lost to follow-up. Clinical exams of the remaining six dogs during the first 3 months did not indicate radiotoxicity induced by MRT. Quality of life improved from 7.3/10 [±0.7] to 8.9/10 [±0.3]. Tumor-induced seizure activity decreased significantly. A significant tumor volume reduction of 69% [±6%] was reached 3 months after MRT. Our study is the first neuro-oncologic veterinary trial of 3D-conformal Synchrotron MRT and reveals that MRT does not induce acute to subacute radiotoxicity in normal brain tissues. MRT improves quality of life and leads to remarkable tumor volume reduction despite low valley dose delivery. This trial is an essential step towards the forthcoming clinical application of MRT against deep-seated human brain tumors.

oncology
Adaptation of laser interstitial thermal therapy for tumor ablation under MRI monitoring in a rat orthotopic model of glioblastoma

Tavarekere N. Nagaraja,Seamus Bartlett,Katelynn G. Farmer,Glauber Cabral,Robert A. Knight,O. Grahm Valadie,Stephen L. Brown,James R. Ewing,Ian Y. Lee

DOI: https://doi.org/10.1007/s00701-021-05002-y

2021-09-23

Acta Neurochirurgica

Abstract:AbstractBackgroundLaser interstitial thermal therapy (LITT) under magnetic resonance imaging (MRI) monitoring is being increasingly used in cytoreductive surgery of recurrent brain tumors and tumors located in eloquent brain areas. The objective of this study was to adapt this technique to an animal glioma model.MethodsA rat model of U251 glioblastoma (GBM) was employed. Tumor location and extent were determined by MRI and dynamic contrast-enhanced (DCE) MRI. A day after assessing tumor appearance, tumors were ablated during diffusion-weighted imaging (DWI)-MRI using a Visualase LITT system (n = 5). Brain images were obtained immediately after ablation and again at 24 h post-ablation to confirm the efficacy of tumor cytoablation. Untreated tumors served as controls (n = 3). Rats were injected with fluorescent isothiocyanate (FITC) dextran and Evans blue that circulated for 10 min after post-LITT MRI. The brains were then removed for fluorescence microscopy and histopathology evaluations using hematoxylin and eosin (H&E) and major histocompatibility complex (MHC) staining.ResultsAll rats showed a space-occupying tumor with T2 and T1 contrast-enhancement at pre-LITT imaging. The rats that underwent the LITT procedure showed a well-demarcated ablation zone with near-complete ablation of tumor tissue and with peri-ablation contrast enhancement at 24 h post-ablation. Tumor cytoreduction by ablation as seen on MRI was confirmed by H&E and MHC staining.ConclusionsData showed that tumor cytoablation using MRI-monitored LITT was possible in preclinical glioma models. Real-time MRI monitoring facilitated visualizing and controlling the area of ablation as it is otherwise performed in clinical applications.

surgery,clinical neurology
Investigation of High Frequency Irreversible Electroporation for Canine Spontaneous Primary Lung Tumor Ablation

Alayna N. Hay,Kenneth N. Aycock,Melvin Lorenzo,Kailee David,Sheryl Coutermarsh-Ott,Zaid Salameh,Sabrina N. Campelo,Julio P. Arroyo,Brittany Ciepluch,Gregory Daniel,Rafael V. Davalos,Joanne Tuohy

DOI: https://doi.org/10.3390/biomedicines12092038

IF: 4.757

2024-09-08

Biomedicines

Abstract:In this study, the feasibility of treating canine primary lung tumors with high-frequency irreversible electroporation (H-FIRE) was investigated as a novel lung cancer treatment option. H-FIRE is a minimally invasive tissue ablation modality that delivers bipolar pulsed electric fields to targeted cells, generating nanopores in cell membranes and rendering targeted cells nonviable. In the current study, canine patients (n = 5) with primary lung tumors underwent H-FIRE treatment with an applied voltage of 2250 V using a 2-5-2 μs H-FIRE waveform to achieve partial tumor ablation prior to the surgical resection of the primary tumor. Surgically resected tumor samples were evaluated histologically for tumor ablation, and with immunohistochemical (IHC) staining to identify cell death (activated caspase-3) and macrophages (IBA-1, CD206, and iNOS). Changes in immunity and inflammatory gene signatures were also evaluated in tumor samples. H-FIRE ablation was evident by the microscopic observation of discrete foci of acute hemorrhage and necrosis, and in a subset of tumors (n = 2), we observed a greater intensity of cleaved caspase-3 staining in tumor cells within treated tumor regions compared to adjacent untreated tumor tissue. At the study evaluation timepoint of 2 h post H-FIRE, we observed differential gene expression changes in the genes IDO1, IL6, TNF, CD209, and FOXP3 in treated tumor regions relative to paired untreated tumor regions. Additionally, we preliminarily evaluated the technical feasibility of delivering H-FIRE percutaneously under CT guidance to canine lung tumor patients (n = 2). Overall, H-FIRE treatment was well tolerated with no adverse clinical events, and our results suggest H-FIRE potentially altered the tumor immune microenvironment.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas

Sabrina N. Campelo,Melvin F. Lorenzo,Brittanie Partridge,Nastaran Alinezhadbalalami,Yukitaka Kani,Josefa Garcia,Sofie Saunier,Sean C. Thomas,Jonathan Hinckley,Scott S. Verbridge,Rafael V. Davalos,John H. Rossmeisl

DOI: https://doi.org/10.3389/fonc.2023.1171278

IF: 4.7

2023-05-05

Frontiers in Oncology

Abstract:Background Irreversible electroporation (IRE) has been previously investigated in preclinical trials as a treatment for intracranial malignancies. Here, we investigate next generation high-frequency irreversible electroporation (H-FIRE), as both a monotherapy and a combinatorial therapy, for the treatment of malignant gliomas. Methods Hydrogel tissue scaffolds and numerical modeling were used to inform in-vivo H-FIRE pulsing parameters for our orthotopic tumor-bearing glioma model. Fischer rats were separated into five treatment cohorts including high-dose H-FIRE (1750V/cm), low-dose H-FIRE (600V/cm), combinatorial high-dose H-FIRE + liposomal doxorubicin, low-dose H-FIRE + liposomal doxorubicin, and standalone liposomal doxorubicin groups. Cohorts were compared against a standalone tumor-bearing sham group which received no therapeutic intervention. To further enhance the translational value of our work, we characterize the local and systemic immune responses to intracranial H-FIRE at the study timepoint. Results The median survival for each cohort are as follows: 31 days (high-dose H-FIRE), 38 days (low-dose H-FIRE), 37.5 days (high-dose H-FIRE + liposomal doxorubicin), 27 days (low-dose H-FIRE + liposomal doxorubicin), 20 days (liposomal doxorubicin), and 26 days (sham). A statistically greater overall survival fraction was noted in the high-dose H-FIRE + liposomal doxorubicin (50%, p = 0.044), high-dose H-FIRE (28.6%, p = 0.034), and the low-dose H-FIRE (20%, p = 0.0214) compared to the sham control (0%). Compared to sham controls, brain sections of rats treated with H-FIRE demonstrated significant increases in IHC scores for CD3+ T-cells (p = 0.0014), CD79a+ B-cells (p = 0.01), IBA-1+ dendritic cells/microglia (p = 0.04), CD8+ cytotoxic T-cells (p = 0.0004), and CD86+ M1 macrophages (p = 0.01). Conclusions H-FIRE may be used as both a monotherapy and a combinatorial therapy to improve survival in the treatment of malignant gliomas while also promoting the presence of infiltrative immune cells.

oncology
First-In-DOg HISTotripsy for Intracranial Tumors Trial: The FIDOHIST Study

Christina Vezza,Lauren Ruger,Maya Langman,Elliana Vickers,Francesco Prada,Jonathan Sukovich,Timothy Hall,Zhen Xu,Rell L. Parker,Eli Vlaisavljevich,John H. Rossmeisl

DOI: https://doi.org/10.1177/15330338241285158

2024-10-19

Technology in Cancer Research & Treatment

Abstract:Technology in Cancer Research &Treatment, Volume 23, Issue , January-December 2024. ObjectiveBrain tumors represent some of the most treatment refractory cancers, and there is a clinical need for additional treatments for these tumors. Domesticated dogs are the only other mammalian species which commonly develop spontaneous brain tumors, making them an ideal model for investigating novel therapies. Histotripsy is a non-thermal ultrasonic ablation method that emulsifies tissue through acoustic cavitation. The primary objectives of this prospective study were to assess the feasibility and safety of histotripsy to ablate naturally occurring canine brain tumors. Secondary endpoints included characterization of magnetic resonance imaging (MRI) responses to histotripsy treatment, and exploratory immunogenomic tumor response analyses.MethodsThe study design utilized a treat and resect paradigm, where tumors were approached using craniotomy, partially ablated with histotripsy delivered through the cranial defect, imaged with MRI, and then resected. Dogs were evaluated with clinical, brain MRI, immunopathologic, and genomic examinations before treatment, intraoperatively, and 1, 14, and 42 days post-treatment. Here we report the results of the three dogs with meningiomas, all of which were treated with a custom eight element 1 MHz histotripsy transducer at a pulse repetition frequency of 100 Hz and a treatment dosage of 400 pulses/point.ResultsHistotripsy was successfully delivered to all dogs, resulting in histopathologic evidence of ablations that were sharply demarcated from untreated tumor, with measured treatments approximating planned volumes in 2/3 dogs. One dog experienced an adverse event consisting of transient cerebral edema that was possibly attributable to histotripsy. Histotripsy ablations could be grossly visualized and identified on MRI, with features consistent with hemorrhage and necrosis. Significant expression or upregulation of the damage associated molecular pattern HMGB1, cytokine-cytokine receptor interaction, and NF-κb signaling pathways were observed in histotripsy treated tumors.ConclusionAblation of canine meningiomas with histotripsy through an open cranial window was feasible and clinically well tolerated.

oncology
Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report

Gaetano Urso,Alexandra Gabriela Boncu,Nancy Carrara,Dragos-Teodor Zaman,Luca Malfassi,Silvia Marcarini,Lucia Minoli,Simone Pavesi,Massimo Sala,Eugenio Scanziani,Mario Dolera

DOI: https://doi.org/10.3390/vetsci9100541

IF: 2.518

2022-09-30

Veterinary Sciences

Abstract:Gliomas are the second-most-common primary brain tumors in dogs. Surgery and radiotherapy are established treatment approaches with similar median survival time, whereas conventional chemotherapy is burdened by severe adverse effects. Spinal and leptomeningeal spread of gliomas have been described following radiotherapy treatment alone. The purpose of this study was to evaluate the outcome for four dogs with primary high-grade gliomas in the forebrain without evidence, at diagnosis, of neoplastic invasion along the spinal cord, that were treated with concomitant chemotherapy (temozolomide) and hypofractionated volumetric-modulated arc radiotherapy (VMAT-RT). Temozolomide was selected for its radiosensitive properties, and radiotherapy dose protocols of 37 Gy in 7 fractions or 42 Gy in 10 fractions were used. After an initial complete or partial response, tumors recurred across the cranial–spinal pathway. Post-mortem macroscopic examinations confirmed swollen spinal cord and hyperemic meningeal sleeve, with nodular lesions on the meningeal surface. Microscopically, infiltration of the spinal cord and meninges by neoplastic cells (with features of oligodendrogliomas) were observed. This work seems to suggest that the entire central nervous system should be investigated in diagnostic examinations of canine gliomas. Dose-escalation trials and/or spinal cord prophylaxis treatment could also be evaluated to prevent tumor progression.

veterinary sciences
Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

John H. Rossmeisl,Jamie N. King,John L. Robertson,James Weger-Lucarelli,Subbiah Elankumaran

DOI: https://doi.org/10.3390/cancers16030564

2024-01-29

Cancers

Abstract:Neurotropic oncolytic viruses are appealing agents to treat brain tumors as they penetrate the blood–brain barrier and induce preferential cytolysis of neoplastic cells. The pathobiological similarities between human and canine brain tumors make immunocompetent dogs with naturally occurring tumors attractive models for the study of oncolytic virotherapies. In this dose-escalation/expansion study, an engineered Lasota NDV strain targeting the urokinase plasminogen activator system (rLAS-uPA) was administered by repetitive intravenous infusions to 20 dogs with intracranial tumors with the objectives of characterizing toxicities, immunologic responses, and neuroradiological anti-tumor effects of the virus for up to 6 months following treatment. Dose-limiting toxicities manifested as fever, hematologic, and neurological adverse events, and the maximum tolerated dose (MTD) of rLAS-uPA was 2 × 107 pfu/mL. Mild adverse events, including transient infusion reactions, diarrhea, and fever were observed in 16/18 of dogs treated at or below MTD. No infectious virus was recoverable from body fluids. Neutralizing antibodies to rLAS-uPA were present in all dogs by 2 weeks post-treatment, and viral genetic material was detected in post-treatment tumors from six dogs. Tumor volumetric reductions occurred in 2/11 dogs receiving the MTD. Systemically administered rLAS-uPA NDV was safe and induced anti-tumor effects in canine brain tumors, although modifications to evade host anti-viral immunity are needed to optimize this novel therapy.

oncology
Chemotherapy for the treatment of intracranial glioma in dogs

Roberto José-López

DOI: https://doi.org/10.3389/fvets.2023.1273122

IF: 3.471

2023-10-31

Frontiers in Veterinary Science

Abstract:Gliomas are the second most common primary brain tumor in dogs and although they are associated with a poor prognosis, limited data are available relating to the efficacy of standard therapeutic options such as surgery, radiation and chemotherapy. Additionally, canine glioma is gaining relevance as a naturally occurring animal model that recapitulates human disease with fidelity. There is an intense comparative research drive to test new therapeutic approaches in dogs and assess if results translate efficiently into human clinical trials to improve the poor outcomes associated with the current standard-of-care. However, the paucity of data and controversy around most appropriate treatment for intracranial gliomas in dogs make comparisons among modalities troublesome. To further inform therapeutic decision-making, client discussion, and future studies evaluating treatment responses, the outcomes of 127 dogs with intracranial glioma, either presumed ( n = 49) or histologically confirmed ( n = 78), that received chemotherapy as leading or adjuvant treatment are reviewed here. This review highlights the status of current chemotherapeutic approaches to intracranial gliomas in dogs, most notably temozolomide and lomustine; areas of novel treatment currently in development, and difficulties to consensuate and compare different study observations. Finally, suggestions are made to facilitate evidence-based research in the field of canine glioma therapeutics.

veterinary sciences
A Pilot Study Using Nanoparticles and Laser Induced Photothermal Ablation to Treat Low Grade Canine Mast Cell Tumors: Evaluation of Efficacy and Safety

Lisa Parshley,Lisa A. Miller,Luis Taboada,Chelsea Tripp,Scott Gustafson,Abbey Bradley,Tammy Melton,Shane Sitzman,Evan Pape,Emily Mouat,Andrew Rosenfeld

DOI: https://doi.org/10.21203/rs.3.rs-659087/v1

2021-08-26

Abstract:Abstract Background: Nanoparticles for over forty years have been the subject of a large number of physical and bioscience research . In the last decade use of these particles in medicine has gone from theoretical to clinical trials. Passive targeting of metal-based nanoparticles takes advantage of inherent abnormalities in tumor vasculature allowing accumulation in solid tumors through a process known as the ‘‘enhanced permeability and retention’’ (EPR) effect. In animal tumor implant models, combination of gold and silicone nanoparticle (GSN) and exposure of tumors to laser light (at 808nm) generated enough heat to cause tumor cell death. Mast cell tumors (MCT) are the most common skin tumor in dogs, with an estimate of MCT being roughly 20% of canine skin tumors. The goal of this pilot study is to evaluate nanoparticle and laser tumor thermal ablation on low grade canine MCT model. Results: 38 dogs with 44 mast cell tumors were enrolled in this prospective pilot study. All control tumors and those biopsied prior to laser therapy were found to be low grade MCT by histopathology (two grade method). After random number generation 8 dogs were assigned to control group and 30 dogs were assigned to treatment group. Treatment group had 36 total tumors and control group had 8 tumors present at time of enrollment. Treatment dogs had a 100% response rate, with 94% achieving clinical remission (34 tumors). Recurrence rate was 17% in those tumors achieving clinical remission. Mean progression free time (PFT) for the treatment group was 552 days and mean PFT for the control group was 1095 days. Conclusion: In conclusion results of this study suggest that photothermal ablation using gold-silicone nanoparticles and exposure to near infrared light (808 nm) provides an effective local therapy of low-grade mast cell tumors. Median progression free time and survival was not reached in our treatment group. Suggesting that long term tumor control is possible with PTA that potentially equals surgery when margins are narrow (<0.3cm) or incomplete. PTA appears to have better and more durable MCT responses than either radiation therapy and electrochemotherapy when used as sole therapies.
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

Mark R. Albertini,Cindy L. Zuleger,Erik A. Ranheim,Oyewale Shiyanbola,Paul M. Sondel,Zachary S. Morris,Jens Eickhoff,Michael A. Newton,Irene M. Ong,Rene Welch Schwartz,Rubi Hayim,Ilene D. Kurzman,Michelle Turek,David M. Vail

DOI: https://doi.org/10.1097/cmr.0000000000000975

2024-06-27

Melanoma Research

Abstract:Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral–immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral–immunocytokine at 12 mg/m 2 on 3 consecutive days. Serial tumor biopsies were obtained. All 12 dogs completed protocol treatment, and none experienced significant or unexpected adverse events. Evidence of antitumor activity includes one dog with a complete response at day 60, one dog with a partial response at day 60, and four dogs with mixed responses. Histology of serial biopsies shows a variably timed increase in intratumoral lymphocytic inflammation in some dogs. Canine NanoString analyses of serial biopsies identified changes in gene signatures of innate and adaptive cell types versus baseline. There were no significant differences in NanoString results between arm A and arm B. We conclude that intratumoral–immunocytokine in combination with local radiation therapy in canine melanoma is well tolerated and has antitumor activity with the potential to inform clinical development in melanoma patients.

dermatology,oncology,medicine, research & experimental
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

Kara Magee,Ian R Marsh,Michelle M Turek,Joseph Grudzinski,Eduardo Aluicio-Sarduy,Jonathan W Engle,Ilene D Kurzman,Cindy L Zuleger,Elizabeth A Oseid,Christine Jaskowiak,Mark R Albertini,Karla Esbona,Bryan Bednarz,Paul M Sondel,Jamey P Weichert,Zachary S Morris,Reinier Hernandez,David M Vail

DOI: https://doi.org/10.1371/journal.pone.0255798

IF: 3.7

2021-08-12

PLoS ONE

Abstract:Rationale: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety and feasibility of this approach in a relevant translational companion dog model (n = 17 dogs) with advanced cancer. Methods: The three component of the combination immuno-radiotherapy approach were employed either separately or in combination in companion dogs with advanced stage cancer. In situ vaccination was achieved through the administration of hypofractionated external beam radiotherapy and intratumoral hu14.18-IL2 fusion immunocytokine injections to the index tumor. In situ vaccination was subsequently combined with targeted radionuclide therapy using a theranostic pairing of IV 86Y-NM600 (for PET imaging and subject-specific dosimetry) and IV 90Y-NM600 (therapeutic radionuclide) prescribed to deliver an immunomodulatory 2 Gy dose to all metastatic sites in companion dogs with metastatic melanoma or osteosarcoma. In a subset of dogs, immunologic parameters preliminarily assessed. Results: The components of the immuno-radiotherapy combination were well tolerated either alone or in combination, resulting in only transient low grade (1 or 2) adverse events with no dose-limiting events observed. In subject-specific dosimetry analyses, we observed 86Y-NM600 tumor:bone marrow absorbed-dose differential uptakes ≥2 in 4 of 5 dogs receiving the combination, which allowed subsequent safe delivery of at least 2 Gy 90Y-NM600 TRT to tumors. NanoString gene expression profiling and immunohistochemistry from pre- and post-treatment biopsy specimens provide evidence of tumor microenvironment immunomodulation by 90Y-NM600 TRT. Conclusions: The combination of external beam radiotherapy, intratumoral immunocytokine, and targeted radionuclide immuno-radiotherapy known to have activity against syngeneic melanoma in murine models is feasible and well tolerated in companion dogs with advanced stage, spontaneously arising melanoma or osteosarcoma and has immunomodulatory potential. Further studies evaluating the dose-dependent immunomodulatory effects of this immuno-radiotherapy combination are currently ongoing.
Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors

Yuta Nishiyama,Takuya Maruo,Yasuhiro Fukuyama,Yuka Odaka,Eiyu Kawata,Hirona Ueno,Hideki Kayanuma,Tomohiro Nakayama,Hiroki Takahashi

DOI: https://doi.org/10.1292/jvms.23-0455

2024-11-01

Abstract:Intranasal tumors in dogs are malignant solid tumors that are primarily treated with radiotherapy and often recur post-treatment. Combination therapy is pivotal in cancer therapy. Effective drugs include fluoropyrimidine 5-fluorouracil (5-FU) and toceranib phosphate. TS-1, an oral formulation containing the 5-FU prodrug tegafur and enzyme modulators gimeracil and oteracil, is proven to be safe in dogs with solid tumors. While the oral drug toceranib phosphate (Palladia®) is safely administered, the combined toxicity with TS-1 is unknown. We aimed to determine the dosage of this combination in dogs. In the preclinical/clinical trials conducted here, we used a standard 3+3 cohort design with fixed doses of toceranib phosphate (2.4 mg/kg) administered thrice weekly. TS-1 administration was initiated at a dose of 0.5 mg/kg (upper limit 2.0 mg/kg) thrice weekly. Four cohorts were included to confirm the safety of TS-1 and toceranib phosphate. Each cohort was followed up for 1 month. The intranasal tumor types included in the clinical trial (n=13) were adenocarcinoma (n=7), squamous cell carcinoma (n=1), non-epithelial malignancy (n=2), undifferentiated carcinoma (n=1), and transitional carcinoma (n=2). The TS-1 dosage could be increased up to its dose limit in the preclinical/clinical trials. The TS-1 dose to combine with toceranib phosphate thrice weekly was 2.0 mg/kg. This regimen was well-tolerated in dogs. Thus, combined TS-1 and toceranib phosphate therapy is safe for dogs with intranasal tumors.
Irreversible Electroporation Balloon Therapy for Palliative Treatment of Obstructive Urethral Transitional Cell Carcinoma in Dogs

Emmanuelle Marie Butty,Bruce Forsyth,Mary Anna Labato

DOI: https://doi.org/10.5326/JAAHA-MS-7160

2022-09-01

Abstract:Progression of transitional cell carcinoma (TCC) in dogs often leads to urinary obstruction. This observational pilot study aimed to evaluate the safety and efficacy of irreversible electroporation (IRE) balloon therapy for the palliative treatment of TCC with partial urethral obstruction. Three client-owned dogs diagnosed with TCC causing partial urethral obstruction were enrolled. After ultrasonographic and cystoscopic examination, IRE pulse protocols were delivered through a balloon catheter device inflated within the urethral lumen. After the procedure, the patients were kept overnight for monitoring and a recheck was planned 28 days later. No complication was observed during the procedure and postprocedural monitoring. After 28 days, one dog had a complete normalization of the urine stream, one dog had stable stranguria, and one dog was presented with a urethral obstruction secondary to progression of the TCC. On recheck ultrasound, one dog had a 38% diminution of the urethral mass diameter whereas the other two dogs had a mass stable in size. IRE balloon therapy seems to be a feasible and apparently safe minimally invasive novel therapy for the palliative treatment of TCC causing urethral obstruction. Further studies are needed to better characterize the safety, efficacy, and outcome of this therapy.
DIPG-18. MULTIMODALITY VISUALIZATION OF A PRECLINICAL MODEL OF DIFFUSE MIDLINE GLIOMA DEMONSTRATES CLEAR TREATMENT EFFECT AFTER RNA NANOPARTICLE THERAPY

Rachel Moor,Frances Weidert,Christina von Roemeling,Jonathan Chardon Robles,Matthew Merritt,Anna Rushin,Guarav Sharma,James McGuiness,Nagheme Thomas,Anna DeVries,Sadeem Qdaisat,Dingpeng Zhang,Maryam Rahman,Elizabeth Ogando-Rivas,Paul Castillo,Ashley Ghiaseddin,Sheila Carrera-Justiz,Duane Mitchell,Hector Mendez-Gomez,Natalie Silver,John Ligon,Elias Sayour

DOI: https://doi.org/10.1093/neuonc/noae064.071

2024-06-18

Neuro-Oncology

Abstract:Abstract BACKGROUND Diffuse Midline Glioma (DMG) is an inoperable pediatric brain tumor with insufficient treatment options. Our group has developed a novel treatment modality for this disease and others, using mRNA vaccines consisting of tumor derived antigens in a unique lipid-nanoparticle (NP). METHODS We have treated mice, canines, and human patients with primary brain tumors to define local immunotherapuetic treatment response. We treated our neonatally implanted DMG model with NPs generated from total-tumor mRNA beginning day 31 and used MRI, MR spectroscopy, suprerspectral imaging, and immunofluorescence to visualize and quantify treatment effects. RESULTS In canine glioma patients enrolled in clinical trial, we visualized radiographically enlarging tumors of animals that ultimately became long-term survivors, supporting the concept of a process by which lesion size increases in the absence of true disease progression. In our clinical trials investigating NPs as a treatment for human and canine glioma, we found features of both reactive gliosis and traditional pseudoprogression (immune infiltration), suggesting a new radiographic diagnosis, thus named paraprogression. In mice bearing DMG, NP therapy led to long-term survivors, despite the development of hydrocephalus. We were able to visualize treatment response during the course of NP therapy using MRI. CONCLUSIONS These results are rapidly translatable to aid clinical decision making in patients with brain tumors treated with immunotherapy. Future studies will aim to mitigate effect of paraprogression without compromising benefit of NP therapy.

oncology,clinical neurology

[Chronic ischemia of the small intestine in carcinoid tumor].

Irreversible Electroporation for the Treatment of Brain Tumors: Pre-clinical Results in a Canine Model of Spontaneous Glioma

High-Frequency Irreversible Electroporation for Intracranial Meningioma: A Feasibility Study in a Spontaneous Canine Tumor Model

Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma

Mechanical Nanosurgery of Chemoresistant Glioblastoma Using Magnetically Controlled Carbon Nanotubes

Intracranial nonthermal irreversible electroporation: in vivo analysis

EXTH-52. GLIOBLASTOMA-TARGETING AUTOLOGOUS INDUCED NEURAL STEM CELL THERAPY: EVALUATING SAFETY, TOXICITY, PERSISTENCE, AND TRANSPLANT METHODS IN A POST-SURGICAL CANINE MODEL

Neuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs

Adaptation of laser interstitial thermal therapy for tumor ablation under MRI monitoring in a rat orthotopic model of glioblastoma

Investigation of High Frequency Irreversible Electroporation for Canine Spontaneous Primary Lung Tumor Ablation

High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas

First-In-DOg HISTotripsy for Intracranial Tumors Trial: The FIDOHIST Study

Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

Chemotherapy for the treatment of intracranial glioma in dogs

A Pilot Study Using Nanoparticles and Laser Induced Photothermal Ablation to Treat Low Grade Canine Mast Cell Tumors: Evaluation of Efficacy and Safety

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors

Irreversible Electroporation Balloon Therapy for Palliative Treatment of Obstructive Urethral Transitional Cell Carcinoma in Dogs

DIPG-18. MULTIMODALITY VISUALIZATION OF A PRECLINICAL MODEL OF DIFFUSE MIDLINE GLIOMA DEMONSTRATES CLEAR TREATMENT EFFECT AFTER RNA NANOPARTICLE THERAPY